An expected delay in a key step in CK Hutchison's planned sale of its Panama ports to a U.S. group, a deal blasted by Chinese ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

Semaglutide, a diabetes drug, significantly lowers the risk of heart attacks and strokes in people with type 2 diabetes.

Use of GLP-1RA therapies in CV/CKD disease with T2D will likely rise as physicians view them as addressers of cardiometabolic ...

Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus® (oral ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...